Please ensure Javascript is enabled for purposes of website accessibility

Why Vaxart Stock Slumped Today

By Prosper Junior Bakiny – Updated Apr 28, 2020 at 5:02PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company released preliminary first-quarter results.

What happened

Shares of Vaxart (VXRT -8.15%), a clinical-stage biotech focused on the development of orally administered vaccines, were down by 10.7% on Tuesday. The market is responding to the company's corporate update, which previewed Vaxart's financial results for the first quarter. 

So what

In its corporate update, the company said it expects to release additional data "within days" on its pre-clinical trial testing several potential COVID-19 vaccines. Vaxart had previously released preliminary data for this trial, noting that several of its investigational vaccines for the coronavirus had generated immune responses in all tested animals after a single dose.

Nurse filling up a syringe with liquid from a glass vial.

Image source: Getty Images.

With that said, the little first-quarter financial data that Vaxart shared in its corporate update was a bit of a mixed bag. The company reported that its cash balance at the end of the quarter was $29.9 million, a 256% year-over-year increase. But revenue of $2.8 million plunged by about 48% compared with the first quarter of the previous fiscal year. Vaxart's double-digit losses on the stock market today can likely be attributed to its disappointing revenue for the first quarter of 2020. 

Now what

Vaxart's stock is still up by more than 800% year to date. With the company racing to develop a vaccine for COVID-19, investors are hopeful that it will make a fortune off of it, and reward its shareholders in the process. Whether the biotech company can pull that off, however, remains highly unlikely. With no approved products on the market and an inflated stock price due to the faint hope that it will manage to win the race to market a COVID-19 vaccine, Vaxart doesn't look particularly attractive at the moment. 

Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Vaxart, Inc. Stock Quote
Vaxart, Inc.
VXRT
$2.14 (-8.15%) $0.19

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
342%
 
S&P 500 Returns
107%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.